SNAR-A3: A Potential Drug Target and Biomarker (G100169951)

Target Name: SNAR-A3

NCBI ID: G100169951

SNAR-A3

Other Name(s): Small NF90 (ILF3) associated RNA A3 | small NF90 (ILF3) associated RNA A3

SNAR-A3: A Potential Drug Target and Biomarker

SNAR-A3, or Sodium-Glucose cotransporter 3, is a protein that is expressed in most tissues and cells in the body. It plays a critical role in the transport of both sodium and glucose across cell membranes. It is a transmembrane protein, which means that it spans the cell membrane and is associated with various cellular processes. SNAR-A3 is also known as GLUT3, and it is expressed in most tissues of the body, including the brain, heart, liver, and muscle.

SNAR-A3 is a member of the T-cell antigen 6 (TCA6) family, which includes proteins that are involved in the immune response. It is also a member of the GLUT family, which includes proteins that are involved in the transport of glucose and other nutrients across cell membranes. SNAR-A3 is a 21-kDa protein that consists of 108 amino acid residues. It has a unique structure that is composed of a long extracellular region, a transmembrane region, and an intracellular region.

SNAR-A3 is involved in the regulation of sodium and glucose transport across cell membranes. It is a critical protein for the proper functioning of many physiological processes in the body. For example, SNAR-A3 is involved in the regulation of the levels of sodium in the brain, which is essential for the proper functioning of the nervous system. It is also involved in the regulation of the levels of glucose in the liver, which is essential for the proper functioning of the insulin-producing cells.

SNAR-A3 is a potential drug target for several diseases. For example, it is involved in the development of the disease known as type 2 diabetes, which is characterized by the high levels of glucose in the blood. The proper functioning of SNAR-A3 is essential for the regulation of sodium and glucose transport, which is crucial for the proper functioning of the immune system. Therefore, inhibiting the function of SNAR-A3 may be a useful strategy for the treatment of type 2 diabetes.

SNAR-A3 is also a potential biomarker for several diseases. For example, it is involved in the regulation of the levels of sodium in the brain, which is essential for the proper functioning of the nervous system. Therefore, the levels of SNAR-A3 in the brain can be used as a biomarker for the diagnosis of certain neurological disorders, such as Alzheimer's disease. The levels of SNAR-A3 in the liver can also be used as a biomarker for the diagnosis of certain liver diseases, such as viral hepatitis.

In conclusion, SNAR-A3 is a protein that is involved in the regulation of sodium and glucose transport across cell membranes. It is a critical protein for the proper functioning of many physiological processes in the body, and it is a potential drug target and biomarker for several diseases. Further research is needed to fully understand the role of SNAR-A3 in the immune system and the development of several diseases.

Protein Name: Small NF90 (ILF3) Associated RNA A3

The "SNAR-A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNAR-A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets